Our group conducts research using multi-omics and immune characterization of solid tumours and liquid biopsies at several layers, with the goal of taking cancer patient therapy towards personalization and achieving a better understanding of tumour genomic and immune heterogeneity.

With IrsiCaixa Cell Virology and Immunology (VIC) group and Barcelona Supercomputing Center teams, our group is working on co-developing a therapeutic neoantigen cancer vaccine for clinical application. As one of the two pillars of cancer vaccine development at IrsiCaixa, our group will coordinate the clinical side, translating next-generation sequencing-guided and experimental analyses of neoantigen prediction to therapeutic benefits for patients with cancer.